Toripalimab in patients with previously treated advanced upper tract urothelial carcinoma: a subgroup analysis of the phase II POLARIS-03 trial
Toripalimab demonstrated promising activity and manageable safety in pretreated mUTUC. High TMB was associated with numerically improved outcomes, suggesting its potential role as an exploratory biomarker for response to PD-1 blockade in this population.
Authors
- X. N. SHENG
- Haige Chen (ORCID: https://orcid.org/0000-0002-1846-8141)
- Jinchang Wei
- Siming Li (ORCID: https://orcid.org/0000-0002-4566-9483)
- Ziling Liu
- Xieqiao Yan (ORCID: https://orcid.org/0000-0002-1781-3193)
- H. Guo
- Ruiyun Zhang
- Juan Li
- Jun Guo
- Bin Hu
Institutions
- Jilin University (CN)
- Renji Hospital (CN)
- Nanjing Drum Tower Hospital (CN)
- First Hospital of Jilin University (CN)
- Ministry of Education (ET)
- Liaoning Cancer Hospital & Institute (CN)
- China Medical University (CN)
Publication Details
- Journal
- The Oncologist
- Published
- 2026-02-14
- DOI
- https://doi.org/10.1093/oncolo/oyag050
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00